4D Molecular Therapeutics FDMT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$68.76M— | —— | -$56.88M-4.1% | -$54.66M-13.9% | -$47.97M+3.4% | ||
| $1.27M+4.4% | $1.22M-3.6% | $1.26M+8.1% | $1.17M+10.9% | $1.05M-4.1% | ||
| $4.45M-19.8% | $5.55M+22.9% | $4.52M-8.9% | $4.96M-29.0% | $6.99M-7.8% | ||
| $3.53M-17.8% | $4.3M— | —— | $4.55M+2,036% | -$235K-116% | ||
| -$4.12M-274% | $2.37M-52.4% | $4.98M+60.2% | $3.11M+235% | -$2.31M— | ||
| $670K— | —— | —— | $2.35M-15.6% | $2.78M+99.3% | ||
| $1.38M+1,633% | -$90K0.0% | -$90K-500% | -$15K-7.1% | -$14K— | ||
| $786K+2.9% | $764K+3.0% | $742K+2.8% | $722K+2.7% | $703K+2.2% | ||
| -$878K-3.3% | -$850K-4.4% | -$814K-5.0% | -$775K-2.8% | -$754K-232% | ||
| -$68.13M— | —— | -$46.5M-7.2% | -$43.38M+9.2% | -$47.76M-4.1% | ||
| $0— | —— | —— | $66K-89.5% | $631K-33.5% | ||
| $68.89M+153% | -$128.85M-825% | $17.78M+228% | -$13.85M-143% | $31.95M— | ||
| —— | —— | —— | —— | —— | ||
| $11.48M-89.7% | $111.98M+96,436% | $116K-86.5% | $862K— | $0-100% | ||
| $12.25M— | —— | -$28.6M+49.3% | -$56.37M-257% | -$15.81M+58.6% | ||
| $1.13M-1.1% | $1.15M-0.6% | $1.15M-1.0% | $1.17M-8.0% | $1.27M-31.5% | ||
| $12K— | —— | —— | —— | -$88K-729% | ||
| -$878K-3.3% | -$850K-4.4% | -$814K-5.0% | -$775K-2.8% | -$754K-232% | ||
| $3.99M+26.2% | $3.17M+215% | -$2.75M— | —— | $1.07M-9.8% | ||
| $786K+2.9% | $764K+3.0% | $742K+2.8% | $722K+2.7% | $703K+2.2% | ||
| -$11K— | —— | —— | —— | $631K— | ||
| $1.67M— | —— | —— | —— | $0— | ||
| —— | $1.88M0.0% | $1.88M0.0% | $1.88M0.0% | $1.88M— | ||
| —— | $246K0.0% | $246K0.0% | $246K0.0% | $246K-78.5% | ||
| $0— | —— | —— | —— | $140K— | ||
| $1.38M+1,633% | -$90K0.0% | -$90K-500% | -$15K-7.1% | -$14K— | ||
| -$878K-3.3% | -$850K-4.4% | -$814K-5.0% | -$775K-2.8% | -$754K-232% | ||
| $98K— | —— | —— | —— | $0— | ||
| —— | $76.75K0.0% | $76.75K0.0% | $76.75K0.0% | $76.75K— | ||
| -$68.13M— | —— | -$46.41M-6.8% | -$43.44M+10.2% | -$48.39M-3.4% | ||
| -$68.13M— | —— | -$46.41M-6.8% | -$43.44M+10.2% | -$48.39M-3.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does 4D Molecular Therapeutics generate?
- 4D Molecular Therapeutics (FDMT) generated -$205.8M in operating cash flow over the trailing twelve months.
- What is 4D Molecular Therapeutics's free cash flow?
- After $1.6M of capital expenditures, 4D Molecular Therapeutics's free cash flow was -$206.4M over the trailing twelve months, down 49.1% year over year.
- Where does 4D Molecular Therapeutics's cash flow data come from?
- Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
